OverviewSuggest Edit

Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. It designs new treatments for various forms of cancer, including both hematological cancers and solid tumors. The company offers CAR-T and CAR-NK cell therapies which are an approach in which a patient’s or donor’s T cells or NK cells, respectively, are genetically modified to carry chimeric antigen receptors, or CARs.

TypePublic
Founded2004
HQHouston, TX, US
Websitebellicum.com
Employee Ratings2.7
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2019)107(-38%)
Revenue (FY, 2020)$500 K(-93%)
Share Price (Jan 2022)$1.5
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Bellicum Pharmaceuticals

Rick Fair

Rick Fair

President and Chief Executive Officer, Director
Atabak Mokari

Atabak Mokari

CFO
Jaa Roberson

Jaa Roberson

Vice President, Human Resources
Thierry Darcis

Thierry Darcis

General Manager of Europe
James Brown

James Brown

Chairman
Jim Daly

Jim Daly

Director
Show more

Bellicum Pharmaceuticals Office Locations

Bellicum Pharmaceuticals has offices in Houston and South San Francisco
Houston, TX, US (HQ)
2130 W Holcombe Blvd #800Houston
Houston, TX, US
2710 Reed Rd #160
Houston, TX, US
3730 Kirby Dr #1200-A
South San Francisco, CA, US
Building 83, 611 Gateway Blvd #820
Show all (4)

Bellicum Pharmaceuticals Financials and Metrics

Bellicum Pharmaceuticals Revenue

Bellicum Pharmaceuticals's revenue was reported to be $500 k in FY, 2020
USD

Net income (Q1, 2021)

(11.3m)

EBIT (Q1, 2021)

(8.9m)

Market capitalization (24-Jan-2022)

12.2m

Closing stock price (24-Jan-2022)

1.5

Cash (31-Mar-2021)

28.1m
Bellicum Pharmaceuticals's current market capitalization is $12.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

185.0k1.1m7.1m500.0k

Revenue growth, %

(52%)505%538%

General and administrative expense

21.0m25.0m30.0m15.5m

R&D expense

65.7m71.2m64.5m39.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

154.0k362.0k292.0k516.0k1.4m103.0k

General and administrative expense

5.7m5.4m7.0m7.5m7.5m9.2m4.2m3.8m4.2m2.0m

R&D expense

16.5m18.4m16.4m16.8m19.9m14.3m10.4m11.8m8.1m6.5m

Operating expense total

22.3m23.9m23.5m24.4m27.6m23.5m14.6m15.5m12.3m8.5m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

38.8m43.7m91.0m35.5m

Accounts Receivable

320.0k909.0k303.0k2.0k

Prepaid Expenses

2.4m1.4m884.0k802.0k

Current Assets

101.7m95.3m111.9m39.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

31.8m73.5m53.0m42.3m42.9m99.2m74.6m66.4m53.1m28.1m

Accounts Receivable

421.0k344.0k538.0k947.0k537.0k328.0k46.0k127.0k125.0k375.0k

Prepaid Expenses

2.4m2.5m2.3m2.3m2.0m1.2m1.6m1.5m1.2m1.5m

Current Assets

84.9m132.3m115.5m76.7m59.1m104.9m94.2m68.2m54.5m31.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(91.8m)(98.0m)(112.5m)(7.7m)

Depreciation and Amortization

3.6m6.7m7.2m1.5m

Accounts Payable

(512.0k)460.0k(1.1m)(1.9m)

Cash From Operating Activities

(73.0m)(74.8m)(77.6m)(56.6m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(22.8m)(47.0m)(70.8m)(24.5m)(51.5m)(83.5m)17.6m(25.6m)(26.5m)(11.3m)

Depreciation and Amortization

1.4m3.2m4.9m1.8m3.7m5.5m537.0k925.0k1.2m47.0k

Accounts Payable

(1.3m)(1.8m)(1.4m)(1.8m)(1.7m)(2.5m)(849.0k)(157.0k)(1.3m)(222.0k)

Cash From Operating Activities

(18.7m)(37.7m)(54.4m)(24.6m)(46.0m)(64.8m)(16.3m)(30.5m)(43.3m)(8.3m)
USDFY, 2017

Revenue/Employee

1.4k

Debt/Equity

0.4 x

Debt/Assets

0.3 x

Financial Leverage

1.6 x
Show all financial metrics

Bellicum Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Bellicum Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Bellicum Pharmaceuticals Online and Social Media Presence

Embed Graph

Bellicum Pharmaceuticals Company Culture

  • Overall Culture

    C-

    69/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Bellicum Pharmaceuticals News and Updates

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Confer…

Thinking about buying stock in Skillz, Rigel Pharmaceuticals, Dynavax Technologies, Bellicum Pharmaceuticals, or Baudax Bio?

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SKLZ, RIGL, DVAX, BLCM, and BXRX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Bellicum Pharmaceuticals Inc. (BLCM) Plunges 8.05% on February 18

Bellicum Pharmaceuticals Inc. (BLCM) had a rough trading day for Thursday February 18 as shares tumbled 8.05%, or a loss of $-0.53 per share, to close at $6.05. After opening the day at $6.39, shares of Bellicum Pharmaceuticals Inc. traded as high as $6.80 and as low as $5.96. Volume was 729,628 sha…

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinic…

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor …

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanyi…
Show more

Bellicum Pharmaceuticals Frequently Asked Questions

  • When was Bellicum Pharmaceuticals founded?

    Bellicum Pharmaceuticals was founded in 2004.

  • Who are Bellicum Pharmaceuticals key executives?

    Bellicum Pharmaceuticals's key executives are Rick Fair, Atabak Mokari and Jaa Roberson.

  • How many employees does Bellicum Pharmaceuticals have?

    Bellicum Pharmaceuticals has 107 employees.

  • What is Bellicum Pharmaceuticals revenue?

    Latest Bellicum Pharmaceuticals annual revenue is $500 k.

  • What is Bellicum Pharmaceuticals revenue per employee?

    Latest Bellicum Pharmaceuticals revenue per employee is $4.7 k.

  • Who are Bellicum Pharmaceuticals competitors?

    Competitors of Bellicum Pharmaceuticals include Bluebird Bio, Adaptimmune and Celyad.

  • Where is Bellicum Pharmaceuticals headquarters?

    Bellicum Pharmaceuticals headquarters is located at 2130 W Holcombe Blvd #800Houston, Houston.

  • Where are Bellicum Pharmaceuticals offices?

    Bellicum Pharmaceuticals has offices in Houston and South San Francisco.

  • How many offices does Bellicum Pharmaceuticals have?

    Bellicum Pharmaceuticals has 4 offices.